Corticosteroid Therapy and Chronic Obstructive Pulmonary Disease

Neil R MacIntyre MD FAARC

Introduction
The Rationale for Corticosteroids in COPD
Corticosteroid Risks for Patients With COPD
The Evidence Base for Clinical Efficacy of Corticosteroids in COPD
Recommendations
Summary

Chronic obstructive pulmonary disease is characterized in part by a chronic inflammatory state in the airways (largely from chronic noxious stimuli such as tobacco smoke), punctuated with acute inflammatory exacerbations, which are often infectious. Although pathologically and biochemically different from the inflammation of asthma, the chronic inflammation of chronic obstructive pulmonary disease, especially in subgroups with asthma-like features and especially during exacerbations, might be expected to respond to corticosteroid therapy, as does asthma. Complications from long-term corticosteroid use are important, but they appear less when the corticosteroid is given via the inhaled route. Clinical evidence is particularly strong supporting the use of inhaled corticosteroids to prevent exacerbations and oral corticosteroids to reduce the duration and impact of exacerbations. *Key words: chronic obstructive pulmonary disease, exacerbation, corticosteroids.* [Respir Care 2006;51(3):289–296. © 2006 Daedalus Enterprises]

Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive disorder characterized in part by chronic inflammation of the airways of the lungs.[1–3] This chronic inflammation is complicated by episodes of acute inflammation (often from infection), termed acute exacerbations of COPD (AECOPD).[4] The chronic inflammation of COPD may have different degrees of involvement in different lung regions in different patients. For example, if the disease is more prominent in the proximal airways, symptoms of cough and phlegm predominate (chronic bronchitis). In contrast, if the disease is more prominent in the distal small-airway regions of the lung, there may be concomi-

tant alveolar destruction (emphysema) and the sensation of dyspnea may predominate. The most common cause of COPD is tobacco smoke exposure, although a small percentage of COPD patients are never-smokers and are thought to develop chronic airway inflammation and alveolar destruction from genetically determined impaired airway defenses (eg, alpha-1 antitrypsin deficiency).[1,2]

The prevalence of COPD in the United States has been estimated at between 5 and 10 million people.[1,2] The reason for this estimate variability is that many patients with subclinical COPD have simply not yet been diagnosed, since the development of clinically important symptoms usually requires substantial loss (ie, > 30–50%) of lung function. The natural history of COPD depends heavily upon the continued exposure to tobacco smoke. Specifically, in COPD patients who continue to smoke, the rate of decline in forced expiratory volume in the first second (FEV_1) is several times faster than in those who quit smoking and those without COPD.[5] On average, COPD patients experience 2 AECOPDs each year.[6] The lung recovery from these exacerbations can take several weeks, but it

Neil R MacIntyre MD FAARC is affiliated with Respiratory Care Services, Duke University Medical Center, Durham, North Carolina.

Correspondence: Neil R MacIntyre MD FAARC, Respiratory Care Services, PO Box 3911, Duke University Medical Center, Durham NC 27710. E-mail: neil.macintyre@duke.edu.

may take many more months for the patient to return to baseline lung function.[4,7] Indeed, a patient with an AE-COPD that requires mechanical ventilation may never return to baseline lung function.

There are no medications that reverse the natural history of COPD, and COPD therapy is generally aimed at alleviating symptoms, improving function, and reducing exacerbations and hospitalizations.[3,8,9] Although the inhaled β agonists and anticholinergics are the mainstay of a COPD treatment regimen, corticosteroids can also play an important role.[10] Interestingly, the pattern of corticosteroid use in COPD has changed over the last half century. Long-term oral corticosteroid (OCS) use was a fairly common practice in the mid-to-late 20th century, but it is estimated that now only 4–10% are considered truly *oral-steroid-dependent*.[6,11] In place of OCS has been an increasing use of inhaled corticosteroids (ICS), to improve symptoms and reduce exacerbations (approaching 65% of the COPD population in some studies[12]). A growing evidence base supports the use of short courses of OCS therapy during AECOPDs to shorten the duration and improve the outcomes of the episode.[10] In the remainder of this paper I review the rationale for corticosteroids, the potential problems with corticosteroids, the evidence base supporting the use of corticosteroids, and finally the recommendations from major organizations for how to use corticosteroids in COPD.

The Rationale for Corticosteroids in COPD

It has been known for decades that pharmacologic doses of corticosteroids reduce a variety of inflammatory processes. In the field of respiratory diseases this has been most extensively studied in asthmatic patients, in whom oral, parenteral, and inhaled corticosteroids have been used for both long-term treatment and acute flares of asthma.[13] The question then becomes whether the inflammatory state present in COPD might have a similar response to corticosteroids.[14]

From a cellular and molecular perspective, the inflammation of asthma and COPD have many differences (Table 1).[15] In asthma there is an important immunologic component, with heavy involvement by eosinophils and cluster-of-differentiation (CD4) positive T lymphocytes. In contrast, COPD is a response to noxious agents (eg, tobacco smoke), a disease in which macrophages, neutrophils, and CD8-positive T lymphocytes play major roles. In asthma, important mediators include interleukins IL4, IL5, and IL13, whereas in COPD IL8 and tumor necrosis factor alpha (TNF-α) appear to be more important. In COPD there are also more reactive oxygen species. From a pathology perspective, asthma has epithelial shedding and very little fibrosis. In contrast, COPD has alveolar destruction, airway scarring, airway fibrosis, and squa-

Table 1. Inflammation Characteristics in Asthma and COPD

Inflammation	Asthma	COPD
Cells	Eosinophils	Neutrophils
	CD4+ T cells	CD8+ T cells
	Macrophages + Mast cells	Macrophages +++
Mediators	Leukotriene B4, histamine	Leukotriene B4
	IL-4, IL-5, IL-13	IL-8, TNF-α
	Reactive oxygen species +	Reactive oxygen species +++
Effects	All airways	Peripheral airways
	Little fibrosis	Lung destruction
	Epithelial shedding	Fibrosis + Squamous metaplasia
Response to steroids	+++	±

CD = cluster of differentiation
IL = interleukin
TNF = tumor necrosis factor (Adapted from Reference 15.)

mous metaplasia. From these considerations then, 2 fundamental questions arise:

1. Will the COPD inflammatory process respond to corticosteroid therapy as well as does the asthma inflammatory process?
2. Alternatively, might it be only subgroups of COPD patients with asthma-like pathology patterns who would be amenable to corticosteroid therapy?

Although neutrophil-predominant inflammation is often less responsive to corticosteroid therapy than is eosinophil- or lymphocyte-predominant inflammation,[16] there are features of COPD inflammation that may be amenable to corticosteroid therapy. For example, corticosteroids may enhance β-agonist activity[17] and may reduce the systemic inflammatory state induced by COPD.[18,19] In addition, exhaled biomarkers of inflammation in COPD appear to be reduced by corticosteroids.[20–22] Despite these observations, many of the clinical trials described below found minimal or no corticosteroid effects on lung function. One possible explanation for this discrepancy is that the chronic inflammatory state of COPD, as well as oxidative stress from continued tobacco smoke exposure, may impair corticosteroid receptors.[14]

There are clinical data that suggest that there is an airway hyperresponsive or asthma-like inflammatory process in certain COPD subgroups.[23–25] Hyperresponsiveness in turn might suggest an active inflammatory process amenable to corticosteroid therapy.[26] For example, in 1,116 COPD patients in the Lung Health Study, methacholine responsiveness at doses < 10 mg/mL was seen in 59% of the population.[23] Similarly, in several studies up to 50% of patients with COPD had substantial FEV_1 reversibility after a β-agonist bronchodilator.[24,25] Pathology studies have

also identified that some COPD patients may have asthma-like pathology intermixed with their COPD pathology.[27–31] For example, there are subgroups who appear to have high levels of eosinophils (especially during exacerbations), and these patients seem to be particularly responsive to corticosteroids.[31,32]

Complicating this picture further are the pathological and biochemical patterns of inflammation during AECOPDs.[4,33] These episodes are often characterized by a response to either viral or bacterial pathogens that involves the influx of various inflammatory cells and mediators, and increases in airway hyperresponsiveness. These acute changes might be particularly amenable to corticosteroid therapy.

Taken together, these observations offer the possibility that corticosteroid therapy might have some impact on the chronic inflammation of COPD, but might be expected to have greater impact in COPD patients who have asthma-like features or those experiencing AECOPDs.

Corticosteroid Risks for Patients With COPD

There are a number of potential adverse effects from both short-term and long-term administration of corticosteroids in COPD.[10] ICS, by nature, generally have lower blood levels than OCS, and this may mean less adverse effects with ICS.

Suppression of the hypothalamic-pituitary-adrenal axis has long been known to be a consequence of high-dose corticosteroids.[34] A recent meta-analysis, however, indicated that ICS use causes some suppression but that the suppression appears to be of questionable clinical importance.[35] Osteoporosis and fractures are also known complications of long-term OCS use.[36] Another meta-analysis of ICS use and bone function has indeed shown some reduction in bone density, but no increase in fractures.[3] It is important to note, however, that these data are difficult to interpret in the COPD population, in whom the chronic airway inflammation and tobacco smoking are also well known risk factors for osteoporosis.[37,38] OCS have been associated with peptic ulcer disease,[39] but the effect of ICS use on ulcer disease is not known. Similarly, psychoses are associated with long-term OCS use,[40] but, again, this has not been carefully assessed in ICS usage. Infections increase with higher doses and longer duration of OCS therapy.[41] ICS therapy is associated with local infections such as candidiasis.[42] Glucose control is more difficult with OCS use in COPD.[43] One study showed that 15% of COPD patients using OCS required additional treatment for hyperglycemia, as compared to 4% in the control group.[44] Respiratory muscles are also affected by long-term OCS use,[45] but this has not been observed with ICS use. This myopathy is difficult to evaluate in COPD patients, however, because of the systemic inflammatory nature of COPD and its effects on skeletal muscle function.[46]

Prolonged OCS use is associated with skin breakdown and bruising.[47] Moreover, high-dose ICS use is associated with bruisability.[48] Finally, OCS use is associated with an increased risk of cataracts,[49] and ICS use in COPD is associated with a 3-fold higher risk for cataracts[50] and a 1.44 odds ratio for glaucoma.[51]

Taken together, these data remind us that corticosteroids pose potentially important risks to patients. This is particularly true with long-term high-dose OCS. ICS use appears to have considerably fewer adverse effects, but the effects are important and need to be considered in making the decision to give a patient corticosteroid therapy.

The Evidence Base for Clinical Efficacy of Corticosteroids in COPD

Studies of adrenocorticotropic hormone for chronic airway diseases other than asthma were first reported in the 1950s.[52,53] These studies, however, were observational in nature, had pulmonary function as the primary end point, and used only very short courses of adrenocorticotropic hormone. Moreover, the study populations were complicated by patients with sarcoid, asthma, interstitial lung disease, and other chronic lung processes.

In 1999, Callahan et al performed a meta-analysis of the trials that had been published up to that date, that used OCS therapy in COPD.[54] These studies generally evaluated short-term uses of corticosteroids (eg, $\leq$ 21 d) and the end point was almost always an increase in FEV_1. In this meta-analysis, using a 20% improvement in FEV_1 as an indication of benefit, the weighted mean effect was 10–11% (95% confidence interval 4–18%). There was a range of 0–56% responders in these studies. What this means is that only a small fraction of COPD patients would seem to have objective physiologic benefits from a short course of OCS. Unfortunately, this meta-analysis was unable to identify how these patients could be identified a priori, although it did suggest that more severe forms of COPD might be more amenable to OCS therapy.

Since that meta-analysis, a few other studies have assessed the role of OCS use in stable COPD patients.[55–57] Two studies of note compared OCS and placebo therapy in COPD patients by measuring FEV_1 response. Robertson et al found that 2 weeks of OCS (versus placebo) produced a comparable FEV_1 response of $\geq$ 20% in 30% of 83 COPD patients.[55] Weir et al studied 127 COPD patients, who were given OCS (versus ICS) for 2 weeks. Forty-two percent of those on OCS had an FEV_1 increase of $\geq$ 20%.[57] As with the Callahan meta-analysis, these studies suggest that a small but important minority of COPD patients do seem to have a response to OCS therapy. All of these studies, however, have examined only short-term physiologic effects and they offer no insight on long-term health-care outcomes in stable COPD patients.

Fig. 1. Meta-analysis of clinical trials that compared the effect of oral corticosteroids versus placebo in preventing exacerbations of chronic obstructive pulmonary disease. The pooled results indicate a benefit from oral corticosteroids. CI = confidence interval. DF = degrees of freedom. (From Reference 60, with permission.)

Two observational studies lasted several years and looked at the long-term FEV_1 decline associated with OCS use in stable COPD. Postma et al[58] studied 139 COPD patients for up to 24 years, and they suggested that the FEV_1 decline appeared slower during periods of higher OCS dosing. Renkema et al followed 58 COPD patients for 2 years.[59] Those on either OCS or ICS therapy had fewer symptoms than patients who did not receive corticosteroids, but there was only a nonsignificant trend toward a slower FEV_1 decline.

In contrast to stable COPD, in which only small subgroups appear to be responders to OCS therapy, the data are much stronger in support of more widespread use of OCS therapy during AECOPDs. These data are summarized in Figure 1 as a meta-analysis, which shows a significant reduction in treatment failures and a more rapid FEV_1 improvement when either oral or systemic corticosteroids are given as part of the AECOPD treatment regimen.[60] The study by Niewoehner et al further showed that 2 weeks of OCS therapy during an AECOPD was just as effective as an 8-week regimen.[61]

ICS were introduced over 25 years ago, initially for treating asthma. ICS, however, have increasingly been given to COPD patients, often to those on long-term OCS therapy, as a way of reducing the oral dose. Supporting this approach are 3 studies that compared short-term OCS and ICS therapy effects on FEV_1. They found that though OCS effects were more prominent, ICS therapy had measurable benefit.[55–57]

A review by van Grunsven et al, in 1999, of 3 placebo-controlled studies with 2-year FEV_1 assessments suggested that ICS therapy improves FEV_1 more than does placebo.[62] A more recent meta-analysis of larger studies by Highland et al, however, showed that FEV_1 decline was not affected by long-term ICS use in COPD (Fig. 2).[63] One 24-week study suggested that adding a long-acting β agonist to ICS therapy would produce a greater FEV_1 response than either agent alone.[64] Supporting this combination approach is the recent observation that withdrawing the ICS component from a combined long-acting-β-agonist-plus-ICS product worsened symptoms.[65]

In contrast to FEV_1 effects, these large trials of ICS therapy in COPD patients did show a significant reduction in AECOPDs with long-term ICS use. This was clearly shown in a meta-analysis by Alsaeedi et al, in 2002 (Fig. 3).[66] A meta-analysis by Sin et al, in 2003, came to a similar conclusion and also demonstrated that long-term ICS use in COPD patients improved quality-of-life scores.[3] Interestingly, the reduction in exacerbations appears to be most prominent in patients who have the most severe reductions in FEV_1.[3]

Importantly, none of these meta-analyses have shown a mortality benefit from long-term ICS therapy. However, in 2 database reviews there was a suggestion that COPD patients who use ICS had a lower mortality than those not taking them, though the studies might have suffered from selection bias.[3] Another large database review suggested that combining ICS with a long-acting β agonist might

Fig. 2. Meta-analysis of clinical trials that compared the effect of inhaled corticosteroids versus placebo on decline in forced expiratory volume in the first second (FEV_1). The pooled results indicate no benefit from inhaled corticosteroids. (From Reference 63, with permission.)

also have a mortality benefit.[67] This combination of ICS plus long-acting β agonist might also further reduce exacerbations, compared to ICS alone.[64]

Recommendations

Several large professional organizations have formulated recommendations to make some clinical sense of the


Fig. 3. Meta-analysis of clinical trials that compared the effect of inhaled corticosteroids versus placebo on preventing exacerbations of chronic obstructive pulmonary disease. The pooled results indicate a benefit from inhaled corticosteroids. (From Reference 66, with permission.)

large amount of data that has accumulated over the last 50 years regarding corticosteroid use in COPD. Two of these, reviewed below, are from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) consortium[8] and the American Thoracic Society and European Respiratory Society (ATS/ERS).[9]

For stable COPD the ATS/ERS guidelines recommend ICS use with patients whose FEV_1 is < 50% of predicted and who have AECOPDs more than once a year. There is also the suggestion that persistent symptoms despite long-acting bronchodilators might warrant a trial of ICS therapy. With a hospitalized patient, during an AECOPD the ATS/ERS recommend OCS at 30–40 mg/d, and if that is not effective, use intravenous corticosteroids for up to 14 days.[9] The ATS/ERS recommendations also state that you could consider ICS therapy in its place, although minimal data support this substitution.

The GOLD consortium recommends that, for stable COPD, ICS therapy should be used with patients who have an FEV_1 of < 50% of predicted and who have had more than 3 AECOPD over the last 3 years. The GOLD recommendations also state that ICS therapy might be helpful for symptoms (but not FEV_1) in some patients who are poorly controlled with bronchodilator therapies. During AECOPDs, GOLD recommends using OCS therapy in patients whose baseline FEV_1 is < 50% of predicted. The recommended dose is 40 mg/d for 10 days. ICS therapy for AECOPDs may be acceptable if the patient is not acidemic.

Interestingly, both ATS/ERS and GOLD recommendations specifically state that there is no place for long-term OCS therapy in stable COPD. However, as noted above, there does appear to be a small fraction of COPD patients who are oral-steroid dependent. Whether these patients

represent a steroid-dependent asthmatic-like subgroup or are simply patients who have not been appropriately and aggressively weaned from OCS therapy after an AECOPD is not clear. Although neither ATS/ERS nor GOLD recommendations specifically address this clinical problem, it would seem reasonable to recommend that every effort should be made to wean the OCS dose, often with the help of ICS therapy, to as low a dose as possible.

Summary

Although pathologically and biochemically different than the inflammation of asthma, the chronic inflammation of COPD, especially in subgroups with asthma-like features, and especially during exacerbations, might be expected to respond to corticosteroid therapy, as does asthma. Complications from long-term corticosteroid use are substantial but appear to be less when given via the inhaled route. Clinical evidence is particularly strong supporting the use of inhaled corticosteroids to prevent exacerbations and oral corticosteroids to reduce the duration and impact of exacerbations. Guidelines from organizations such as the American Thoracic Society and the Global Initiative for Obstructive Lung Disease can be accessed on the Internet to guide therapy.

REFERENCES

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343(4):269–280.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/ WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163(5):1256–1276.
3. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290(17):2301–2312.
4. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119(4):1190–1209.
5. Fletcher C, Peto R. The natural history of chronic airflow obstruction Br Med J 1977;1(6077):1645–1648.
6. Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med 1999;93(3):173–179.
7. Spencer S, Jones PW; GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58(7):589–593.
8. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at www.goldcopd.com. Accessed Dec 22, 2005
9. American Thoracic Society. Available at www.thoracic.org. Accessed Dec 22, 2005.
10. McEvoy CE, Neiwoehner DE. Corticosteroids in chronic obstructive pulmonary disease: clinical benefits and risks. Clin Chest Med 2000; 21(4):739–752.
11. Jackevicius C, Joyce DP, Kesten S, Chapman KR. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. Chest 1997;111(2):296–302.
12. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47–55.
13. Barnes PJ. Molecular basis for corticosteroid action in asthma. Chem Immunol 2000;78:72–80.
14. Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc 2005;2(4):313–319; discussion 340–341.
15. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000;117(2 Suppl):10S–14S.
16. Chanez P, Bourdin A, Vachier I, Godard P, Bousquet J, Vignola AM. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1(3):184–190.
17. Johnson M. Interactions between corticosteroids and β_2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1(3):200–206.
18. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(7):760–765.
19. Man SF, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2(1):78–82.
20. Zietkowski Z, Kucharewicz I, Bodzenta-Lukaszyk A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease. Respir Med 2005;99(7):816–824.
21. Kharitonov SA. Barnes PJ. Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1(3):191–199.
22. Sadowska AM, van Overveld FJ, Gorecka D, Zdral A, Filewska M, Demkow UA, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 2005;99(2):241–249.
23. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343(26):1902–1909.
24. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999;115(4):966–971.
25. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084–1091.
26. Perng DW, Huang HY, Chen HM, Lee YC, Perng RP. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 2004;126(2):375–381.
27. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155(5):1529–1534.
28. Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y. Eosiophilic inflammation in the airway is related to glucocorticoid reversitilibty in patients with pulmonary emphysema. Chest 1999; 115(3):697–702.
29. Lacoste JY, Bousquet J, Chanez P, Van Vyve T, Simony-Lafontaine J, Lequeu N, et al. Eosinophilic and neutrophilic inflammation in

asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92(4):537–548.

30. Linden M, Rasmussen JB, Piitulainen E, Tunek A, Larson M, Tegner H, et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993;148(5): 1226–1232.

31. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158(5 Pt 1):1511–1517.

32. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60(3):193–198.

33. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646–1652.

34. Schlaghecke R, Kornely E, Santen R, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326(4):226–230.

35. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159(9):941–955.

36. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL. Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest 1982;69(6):1302–1309.

37. Daniell HW. Osteoporosis of the slender smoker: vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med 1976; 136(3):298–304.

38. Seeman E, Melton LJ III, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983;75(6):977–983.

39. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309(1):21–24.

40. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972;13(5):694–698.

41. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11(6):954–963.

42. Sulica L. Laryngeal thrush. Ann Otol Rhinol Laryngol 2005;114(5): 369–375.

43. Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax 1968;23(6):571–581.

44. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340(25):1941–1947.

45. Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976;61(4):485–492.

46. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A Statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159(4 Pt 2):S1–S40.

47. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236(6):619–632.

48. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340(25): 1948–1953.

49. Hodge WG, Whitcher JP, Satariano W. Risk factors for age-related cataracts. Epidemiol Rev 1995;17(2):336–346.

50. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280(6): 539–543. *Erratum in: JAMA 1998;280(21):1830.*

51. Garbe E, LeLorier J, Boivin JF, Suisse S. Inhaled and nasal glucorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277(9):722–727.

52. Lukas DS. Some effects of adrenocorticotropic hormone and cortisone on pulmonary function of patients with obstructive emphysema. Am Rev Tuberc 1951;64(3):279–294.

53. Galdston M, Weisenfeld S, Benjamin B, Rosenbluth MB. Effect of ACTH in chronic lung disease: a study of five cases. Am J Med 1951;10(2):166–181.

54. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114(3):216–223.

55. Robertson AS, Gove RI, Wieland GA, Burge PS. A double-blind comparison of oral prednisolone 40 mg/day with inhaled beclomethasone dipropionate 1500 μg/day in patients with adult onset chronic obstructive airways disease. Eur J Respir Dis Suppl 1986;146:565–569.

56. Shim CS, Williams MH Jr. Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease. Am J Med 1985;78(4):655–658.

57. Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisilone and inhaled beclomethasone dipropionate. Thorax 1990; 45(2):112–117.

58. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction: can corticosteroids slow down obstruction? Eur Respir J 1988;1(1):22–26.

59. Renkema TEJ, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109(5):1156–1162.

60. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005 Jan 25; (1):CD001288.

61. Niewoehner DE. Collins D. Erbland ML. Relation of FEV_1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000;161(4 Pt 1):1201–1205.

62. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54(1):7–14.

63. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV_1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 2003;138(12):969–973. *Erratum in: Ann Intern Med 2003;139(10):873.*

64. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg)/ salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124(3):834–843.

65. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Withdrawal of fluticasone pro-

pionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60(6):480–487.

66. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113(1): 59–65.

67. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20(4):819–825.

Alevaire for mucolytic inhalation therapy
Advertisement by Winthrop Laboratories, New York, New York
Inhalation Therapy, Journal of the American Association of Inhalation Therapists
Vol 9, No 5, October 1964